What is HC Wainwright’s Estimate for VRDN FY2027 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – HC Wainwright issued their FY2027 earnings per share estimates for Viridian Therapeutics in a report issued on Tuesday, March 31st. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($3.51) per share for the year. HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ FY2028 earnings at ($2.84) EPS, FY2029 earnings at ($1.33) EPS and FY2030 earnings at $0.71 EPS.

Other equities research analysts also recently issued reports about the stock. Evercore reiterated an “outperform” rating and set a $44.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 20th. Needham & Company LLC reduced their price objective on Viridian Therapeutics from $42.00 to $32.00 and set a “buy” rating for the company in a report on Monday. William Blair initiated coverage on Viridian Therapeutics in a report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Wednesday, January 21st. Finally, The Goldman Sachs Group decreased their price objective on shares of Viridian Therapeutics from $41.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $39.21.

Viridian Therapeutics Stock Down 2.1%

VRDN stock opened at $19.15 on Thursday. The company has a market cap of $1.96 billion, a P/E ratio of -5.82 and a beta of 1.16. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $34.29. The company’s 50-day moving average price is $28.90 and its 200 day moving average price is $27.83. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.08.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Thursday, February 26th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.18). The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $15.75 million. Viridian Therapeutics had a negative net margin of 483.57% and a negative return on equity of 83.25%.

Institutional Trading of Viridian Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd purchased a new position in shares of Viridian Therapeutics during the 4th quarter worth $36,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Viridian Therapeutics in the third quarter valued at $35,000. Farther Finance Advisors LLC grew its position in shares of Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after purchasing an additional 1,491 shares during the period. Bessemer Group Inc. increased its stake in Viridian Therapeutics by 947.7% in the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock valued at $45,000 after purchasing an additional 1,886 shares during the last quarter. Finally, Larson Financial Group LLC purchased a new position in Viridian Therapeutics during the third quarter worth about $52,000.

Viridian Therapeutics News Roundup

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Zacks noted a sharp intraday move — VRDN earlier rallied ~5.6% on above‑average volume, indicating pockets of buying interest and short‑term volatility that can create bounce opportunities. Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock?
• Neutral Sentiment: HC Wainwright made mixed estimate changes (small tweaks to quarterly EPS projections) but maintained a “Buy” stance with a lower $22 target — signaling some analyst conviction remains even as forecasts adjust. (See the MarketBeat/H.C. Wainwright research notes cited in recent reports.)
• Negative Sentiment: A negative Phase‑3 readout for the active thyroid eye disease trial prompted a steep pre‑market decline, which is the primary catalyst for today’s selling pressure and raised clinical/regulatory uncertainty. VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal?
• Negative Sentiment: Goldman Sachs lowered its price target to $36 (from $41), a sign that sell‑side expectations for medium‑term value have been trimmed following the trial news. The Goldman Sachs Group Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $36.00
• Negative Sentiment: Wedbush reduced its outlook (price target lowered to $37 from $44), which contributes to negative market sentiment and reduced upside implied by broker targets. Wedbush Has Lowered Expectations for Viridian Therapeutics (NASDAQ:VRDN) Stock Price
• Negative Sentiment: Wells Fargo cut its price target sharply to $20 and moved to an “equal weight” view, signaling more cautious near‑term expectations from another large brokerage. Wells Fargo & Company Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $20.00
• Negative Sentiment: HC Wainwright also issued a more cautious note in follow‑up coverage (covered by recent press), contributing to the cluster of analyst downgrades and target trims that keep selling pressure elevated. HC Wainwright Issues Pessimistic Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.